Zimbabwe has declined a major American health deal worth $367m (£272m) over five years due to the United States' request for confidential information.
This rejection was revealed following a government memo from December was leaked, revealing that President Emmerson Mnangagwa believed the arrangement was "skewed".
A government spokesperson has since clarified that the US was seeking genetic material for scientific study and profit but was not willing to share the benefits from future vaccines.
"We must now begin the challenging and unfortunate task of scaling back our health aid in Zimbabwe," remarked American envoy to Zimbabwe Pamela Tremont in a statement.
Her embassy said the US had provided over $1.9bn in health funding to Zimbabwe over the last twenty years.
A medical body in Zimbabwe has urged further talks to secure a agreement agreeable to both sides so the country's critical HIV programme can proceed.
Broader Context
Zimbabwe's decision comes after a similar situation in neighbouring Kenya, where a court halted a related deal with the US after legal challenges were raised about the safety of citizens' medical information.
Since resuming the presidency recently, US President Donald Trump has slashed overseas assistance and closed the key foreign aid agency.
The agency had overseen aid for the American government, but Trump argued its spending was "inefficient" and his government was seeking government-to-government agreements to enhance transparency and accountability.
According to reports, 16 African countries have to date signed these new agreements, representing over $18.3bn of fresh investment.
Details of the Declined Agreement
The money for Zimbabwe was intended to gone towards "HIV/Aids treatment and prevention, TB, malaria, maternal and child health, and disease outbreak preparedness.
"We are confident this collaboration might have yielded immense advantages for Zimbabwean communities, particularly the 1.2 million currently receiving HIV treatment via American-funded initiatives," the Ambassador commented.
However, official spokesman Nick Mangwana argued the proposed deal was "unequal".
"Our nation was requested to share its biological resources and data indefinitely, without any corresponding guarantee of benefiting from any medical innovations – like new medicines or tests – that might be developed from that shared data," he stated.
"Put simply, our nation would provide the raw materials for scientific discovery without any assurance that the resulting innovations would be accessible to our population if a future disease outbreak emerge."
Sovereignty and Global Health
He also said that the American exit from the global health body and its pursuit of one-on-one deals were disrupting systems already established via the international health agency.
The spokesperson cited its Pathogen Access and Benefit Sharing scheme designed to deal with potential pandemics.
"This system is designed to guarantee that when a country contributes its data, the benefits – including vaccines and treatments – are shared equitably, not commercialised exclusively by those with the funds to develop them."
These objections regarding the US deal "are not meant as opposition to America," he added.
"We encourage ongoing discussions with our American counterparts on how subsequent co-operation might be structured in a way that respects the sovereignty and interests of both nations."
Medical Community Response
A leading public health body stated it acknowledged the official position, but recommended that negotiations must proceed given that a large portion of the country's HIV programmes were funded by international support.
"In cases where specific concerns exist, such as those involving information security or implementation frameworks, these can often be resolved via technical clarification and negotiated safeguards," the group added.
The situation underscores the continuing challenges between accepting crucial foreign assistance and protecting a country's data in an ever more interconnected world.